Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
- 1 March 2014
- journal article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 133 (3) , 921-923
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- Mepolizumab and Exacerbations of Refractory Eosinophilic AsthmaNew England Journal of Medicine, 2009
- Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levelsJournal of Allergy and Clinical Immunology, 2008
- Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroidsJournal of Allergy and Clinical Immunology, 2005
- Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti–IL-5 antibody SCH55700Journal of Allergy and Clinical Immunology, 2004
- Predictive Markers of Asthma Exacerbation during Stepwise Dose Reduction of Inhaled CorticosteroidsAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Changes in Sputum Eosinophils Predict Loss of Asthma ControlAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Prednisone-dependent asthma: inflammatory indices in induced sputumEuropean Respiratory Journal, 1999